A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: CAB Oral Tablets
DRUG: CAB LA
DRUG: ABC/3TC Oral tablets
DRUG: RPV Oral Tablets
OTHER: HAART
DRUG: RPV

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]